Analysis of von Willebrand factor multimers using a commercially available enhanced chemiluminescence kit

A M Cumming, R T Wensley

Abstract

Aims—To develop a rapid, sensitive, and safe method for the analysis of von Willebrand factor (vWF) multimers in plasma or platelet lysates.

Method—Analysis of vWF multimers was carried out by sodium dodecyl sulphate-agarose discontinuous gel electrophoresis followed by protein transfer to nitrocellulose membranes by western blotting. Blots were probed using horseradish peroxidase (HRP) conjugated rabbit anti-vWF; visualisation of vWF multimers was achieved using a commercially available enhanced chemiluminescence (ECL) kit for detecting HRP labelled antibodies on western blots.

Results—Electrophoretic transfer of vWF multimers to nitrocellulose membranes, including the higher molecular weight forms, was achieved satisfactorily and there was good resolution of individual multimer bands and of the triplet sub-band structure. Type II vWD variants were readily identifiable. The use of ECL conferred a high degree of sensitivity to the method and the end result on autoradiography film provided a permanent record which did not fade and which was suitable for scanning densitometry.

Conclusion—The method for vWF multimer analysis described here is sensitive, simple to carry out, uses minimal amounts of reagents, produces results within 48 hours, and does not require the use of potentially hazardous radioactive materials or carcinogenic enzyme substrates.

(VJ Clin Pathol 1993;46:470-473)

Von Willebrand factor (vWF) is a large multimeric glycoprotein that has essential roles in the adhesion of platelets to subendothelium in primary haemostasis and as a carrier protein for procoagulant factor VIII. It is present in plasma as a range of multimers, assembled from the 250 kilodalton monomer subunit, with molecular weights of up to $20 \times 10^6$ daltons. The analysis of vWF multimers is necessary for the classification of von Willebrand disease (vWD), an autosomally inherited bleeding disorder resulting from quantitative (vWD types I and III) or qualitative (vWD type II variants) abnormalities of vWF. The most common of the inherited bleeding disorders, vWD has a reported incidence in the population as high as 1% or more.

Several different methods have been described for the analysis of vWF multimers in plasma or in platelet lysates. Methods using $^{125}$I-labelled anti-vWF or are sensitive and autoradiography provides a permanent record for future reference or for carrying out scanning densitometry. The use of radioisotopes, however, is potentially hazardous and many laboratories do not have the appropriate facilities. These methods are also time consuming and expensive. Other methods where enzyme-labelled antibodies are used as an alternative to radiolabelled antibodies have the advantages of being more rapid, more economical, and potentially less hazardous to perform. Disadvantages are that some enzyme substrates may be carcinogenic, and the end result is usually unstable, often fragile (for example on nitrocellulose membranes), and not readily subjected to scanning densitometry.

We describe a sensitive, non-radioactive method for the analysis of vWF multimers which can be carried out within 48 hours and which, by the use of enhanced chemiluminescence (ECL) technology, provides a permanent record which does not fade and which is suitable for scanning densitometry.

Methods

ELECTROPHORESIS

Blood was collected on to 1 in 10 volume 0-106 M trisodium citrate. Plasma was separated by centrifugation at 2000 $\times$ g for 15 minutes and stored at $-30^\circ$C until analysis. Analysis of vWF multimers was carried out by SDS-agarose discontinuous gel electrophoresis, using 1.5% agarose for high resolution gels and 1.0% agarose for low resolution gels. Low gelling temperature agarose, type VII (Sigma Chemical Company, Poole, Dorset), was used throughout and electrophoresis was carried out using an LKB Multiphor 2117 system (Pharmacia LKB Biotechnology, Uppsala, Sweden).

Resolving gels were prepared by heating agarose to 100°C in 0-5 M TRIS (pH 8.8), 0-1% SDS. After cooling to 60°C the gel was poured between two glass plates separated by a 1 mm thick U-shaped former to give gel dimensions of $20 \times 10.5$ cm. Gels were supported on Gelbond (Pharmacia LKB Biotechnology). After polymerisation a 2 cm strip was removed from the top of the
resolving gel and the stacking gel (0-8% agarose in 0-125 M TRIS (pH 6-8), SDS 0-1%) was added at 60°C. Subsequent to its polymerisation, 10 sample wells (8 × 2 mm) were cut into the stacking gel 8 mm from its interface with the resolving gel.

Plasma or platelet lysate samples were diluted 1 in 20 in 0-01 M TRIS (pH 8-0), 1 mM Na$_2$EDTA, 2% SDS and incubated at 60°C for 30 minutes. A 1% solution of bromophenol blue (5 µl) was added to each diluted sample for tracking purposes. The diluted samples (20 µl) were transferred into the sample wells and electrophoresis was carried out at a constant current of 30 mA, with cooling to 10°C and using wicks of four layers of 3M chromatography paper (Whatman, Maidstone, Kent). The electrophoresis tank buffer was 0-05 M TRIS, 0-384 M glycerol, 0-1% SDS (pH 8-35).

When the tracking dye front approached the interface of the stacking gel with the resolving gel (30 to 40 minutes) the sample wells were filled with stacking gel. Electrophoresis was then continued at a constant current of 9 mA for about 16 hours until the tracking dye had migrated to the anodal end of the resolving gel.

WESTERN BLOTTING
After electrophoresis the gel was equilibrated for 30 minutes in western blotting transfer buffer (25 mM TRIS, 192 mM glycerol, 20% methanol, 0-1% SDS, pH 8-3). The gel was separated from the Gelbond support by passing a nylon thread between the gel and the Gelbond and then inverting the gel on to a pre-wetted nitrocellulose membrane. Electroblotting was carried out for six hours at 0-3 A and 8°C using a Transphor electroblotting unit (Pharmacia LKB Biotechnology) according to the manufacturer’s instructions.

IMMUNOENZYMATIC DETECTION
Subsequent to western blotting the nitrocellulose membrane was rinsed in 10 mM phosphate buffered saline (PBS), pH 7-4. It was then blocked using 100 ml of 5% low-fat dried milk in PBS, 0-1% Tween 20, in a shaking water bath at 37°C for one hour. Following rinsing with PBS the membrane was placed inside a 200 ml screw-capped cylindrical container (Sterilin Ltd, Hounslow, Middlesex) with the protein side facing inwards. A 1:200 dilution of horseradish peroxidase (HRP) conjugated rabbit anti-vWF (Dako Ltd, High Wycombe, Bucks) in 10 ml PBS/1% low-fat dried milk was added to the container. The membrane was probed overnight at room temperature using roller mixing as described by Thomas et al. The blot was rinsed twice with PBS/0-1% Tween 20 and then washed once for 15 minutes and four times for 3 minutes each using 100 ml volumes of PBS/0-1% Tween 20 with roller mixing.

ENHANCED CHEMILUMINESCENCE (ECL)
Visualisation of vWF multimers was achieved by the use of an ECL kit for the detection of HRP-labelled antibodies on western blots (Amersham International UK). The kit was used according to the manufacturer’s instructions. Briefly, a mixture of equal volumes of reagents 1 and 2 was prepared and poured on to the nitrocellulose membrane. After 1 minute the blot was drained and wrapped in SaranWrap. The treated blot was placed in a film cassette and immediately exposed to autoradiography film (Hyperfilm-ECL, Amersham International). This was carried out in the dark-room using exposure times of 5 to 15 seconds. The exposed films were developed as soon as convenient.

125I-AUTORADIOGRAPHY
Electrophoresis was performed as described above and the gel was probed with 125I-labelled anti-vWF. Multimers were visualised by placing the gel in a film cassette and exposing it, at −70°C, to autoradiography film for 24 to 48 hours as required. The exposed film was developed immediately.

Results
An example of vWF multimer analysis using ECL visualisation is shown in figure 1. A 15 second exposure to autoradiography film was used. At least 16 main multimer bands were consistently distinguishable in normal plasma (lanes 1 and 7) and the triplet sub-band structure was well defined. The absence of the higher molecular weight multimers in type II vWD variants (lanes 3 and 4) was readily apparent using 1-5% agarose gels, and the characteristic enhancement of the triplet sub-bands, often seen in type II variants, was easily discernible. One or two faint comparatively low molecular weight multimers were often present in type III vWD plasma samples (lane 5). The distribution of multimers found in a normal platelet lysate sample can be seen in lane 6.

Figure 2 shows an example of vWF multimer analysis using 125I-autoradiography with 36 hours of exposure to autoradiography film. Resolution of the higher molecular weight bands was inferior to that achieved with ECL and only 11 or 12 main multimer bands were individually distinguishable in normal plasma (lanes 1 and 5). The distribution and resolution of multimers in type II vWD variants (lanes 2 and 3) were similar to those revealed by ECL. No multimer bands were visible in the type III vWD plasma sample (lane 4).

Discussion
The use of luminography for vWF multimer analysis has already been reported by Schnepenheim and colleagues, who described a method using individual reagents for luminography rather than a commercially available kit. These workers (and others) observed incomplete electrophoretic transfer of the higher molecular weight multimers on to nitrocellulose filters, a phenomenon which may cause problems with the identification of type II vWD variants where the higher molec-
ular weight multimers are absent to varying degrees. Budde and coworkers have also described the use of ECL for visualisation of vWF multimers. However, these investigators found it necessary to combine ECL with the use of streptavidin and biotin technology to achieve the required sensitivity. They also reported some difficulty in transferring the largest multimers from the electrophoresis gel to the nitrocellulose membrane.

Using the present method, there was no difficulty in transferring the largest multimer bands (fig 1) and results were comparable with those we have achieved previously by direct 125I-autoradiography of agarose gels (fig 2). Indeed, there was better resolution of the higher molecular weight multimers into discrete bands than we have seen with 125I-autoradiography. The use of the ECL kit conferred a high degree of sensitivity on to the method and there was no need for the use of avidin and biotin reagents. For example, the multimer distribution of a plasma sample containing 0-13 IU/ml of vWF antigen (measured by ELISA) was easily visualised by ECL (fig 1), and the lower molecular weight multimers which were seen in type III vWD when ECL-visualisation was used (fig 1) were not apparent using 125I-autoradiography (fig 2). The latter observation suggested that ECL may in this instance be the more sensitive of these two methods.

The end result on autoradiography film provided a permanent record which did not fade and which was eminently suitable for scanning densitometry. Sensitivity was such that the time required for exposure of blots to autoradiography film was consistently within the range of 5–15 seconds. One advantage arising from this short exposure time was that a number of exposures of the same blot could be produced in a matter of minutes rather than many days as was the case with 125I-autoradiography. Blots could also be washed and stored for repeat ECL processing at a later date if necessary. The processing of the blots using roller mixing16 resulted in very economical use of antisera; about one tenth
or less of the volumes required for conventional methods using plastic bags or trays were used.

In summary, the method described here is simple to carry out, uses minimal amounts of reagents, produces results within 48 hours, and does not require the use of potentially hazardous radioactive materials or carcinogenic enzyme substrates.

Analysis of von Willebrand factor multimers using a commercially available enhanced chemiluminescence kit.
A M Cumming and R T Wensley

doi: 10.1136/jcp.46.5.470

Updated information and services can be found at:
http://jcp.bmj.com/content/46/5/470

**Email alerting service**

Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

**Notes**

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/